Skip to main content
Equibles
TARS logo

TARS · Tarsus Pharmaceuticals, Inc.

Track TARS — free

Use TARS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TARS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$69.20 +0.32 (+0.46%) At close · Aug 14
Market Cap
$3.04B
Shares
43.88M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$69.20 Open$68.82 Day$67.61–69.70 52W close$49.36–82.51 Avg vol 30d1.1M Short int6.0M · 13.7% float · 6.6d Short vol57% Last earningsAug 6, 2026 DataOct 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +1%
      above
      Price vs 50-day avg +11%
      above
      RSI (14) 66
      neutral
      MACD trend Positive
      52-week position 60%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +16%
      trailing
      6-month return −1%
      trailing
      YTD return −15%
      this year
      Relative strength −14%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $62 › 200d $68 — 200d above 50d
      Institutional flow Accumulating
      +1% holders QoQ · +42 funds added
      Insider flow Distributing
      Net -$877.4K over 90 days · 100% sells
      Short interest Rising
      13.71% of float · ▲ +4.0% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      256 holders — near 3-yr high, broad support
      Squeeze score 83
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +147%
      Y/Y
      EPS growth +48%
      Y/Y
      Free cash flow $-22.3M
      Balance sheet $111.2M
      net cash
      Quant / Vol
      risk profile
      High
      Volatility 44%
      annualized · 1-yr
      Max drawdown −32%
      past year
      ATR 4.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 6, 2026
      XDEMVY net product sales · full-year 2026 $685M – $705M
      Prior guidance period ended · from the Earnings Call filed Mar 31, 2024
      Fully burdened cost per sales rep · late Q3 2024 $300,000

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +1% Bullish
      Price vs 50-day avg
      +11% Bullish
      RSI (14)
      66 Neutral
      MACD trend
      Positive Bullish
      52-week position
      60% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $62 › 200d $68 — 200d above 50d
      Institutional flow Accumulating
      +1% holders QoQ · +42 funds added
      Insider flow Distributing
      Net -$877.4K over 90 days · 100% sells
      Short interest Rising
      13.71% of float · ▲ +4.0% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      256 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $49 Now $69 · 60% Range high $83
      vs 200-day avg +1% vs 50-day avg +11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      bottles of XDEMVY delivered to patients 400,000 full-year 2025 —
      commercial, Medicare, and Medicaid covered lives 90% fourth quarter 2025 —
      gross-to-net discount 45% full-year 2025 —
      Unaided awareness of Demodex blepharitis 25% full-year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      TARS
      Tarsus Pharmaceuticals, Inc.
      this stock
      		$3.04B -15.5% +146.7% — 13.7%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      256
      % held
      109.4%
      Net QoQ
      +2.4M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      250
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      6.0M
      Days to cover
      6.6d
      Change
      +233.8K sh
      View
      Short Volume
      Short vol %
      57%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5.3K
      Value
      $315.3K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      58.1%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$877.4K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $451.4M
      Net income (FY)
      $-66.4M
      EPS diluted
      $-1.59
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      19
      View
      Proposed Sales
      Value
      $877.5K
      Shares
      14.4K
      Filed
      Jun 16, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View
      Investor Relations
      Latest news
      Tarsus Reports Second Quarter 202…
      Published
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      TARS +6.8% +15.6% -0.6% +17.2% -15.5%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +6.4% +11.2% -14.3% +13.3% -29.3%
      Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 246 filings 243 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)